Kangstem Biotech

Organoid

Organoids are biologically relevant, three-dimensional models that recapitulate the structure and function of human organs, derived from human stem cells. By faithfully reproducing cell–cell interactions and tissue-specific microenvironments, organoids overcome the inherent limitations of conventional two-dimensional cell cultures and animal models, positioning them as a next-generation research platform.

The global organoid market is predominantly driven by drug discovery and high-throughput screening, which accounts for approximately 40% of total applications. This is followed by disease modeling (25%) and toxicity testing (15%). In addition, regenerative medicine (10%) and other emerging applications continue to expand, highlighting a clear transition of organoid technology from a research-focused tool toward broader clinical and therapeutic applications.

Since 2021, the global organoid market has experienced double-digit compound annual growth, reflecting rapid expansion across biomedical research and pharmaceutical development. Looking ahead, the market is expected to enter an accelerated growth phase beyond 2025, driven by increasing demand for drug development, precision medicine, and human-relevant alternative testing platforms.

Kangstem Biotech’s skin organoids are human-relevant, three-dimensional models that faithfully recapitulate the structure and function of native human skin, derived from human stem cells. By simultaneously reconstructing key skin components—including the epidermis, dermis, and hair follicles—these organoids provide a more accurate representation of human skin biology than conventional simplified cell culture models.
In particular, the use of an air–liquid interface (ALI) culture system enables a high degree of structural and functional similarity to in vivo human skin. Compared to traditional cyst-based organoid models, this approach offers a more efficient and user-friendly testing environment, supporting robust and reproducible experimental workflows.
Furthermore, this platform enables the direct provision of skin organoids suitable for drug screening and hair follicle transplantation-related applications, expanding their utility across pharmaceutical research and regenerative medicine.

Skin Organoid Culture Method

Kangstem Biotech has developed a proprietary skin organoid technology that delivers structurally
and functionally superior, high-purity organoids with enhanced similarity to native human skin,
surpassing conventional skin organoid generation methods.

Air-Liquid Interface(ALI) Culture

The air–liquid interface (ALI) culture system used in skin organoid development allows the epidermal layer
to be directly exposed to air while the underlying skin layers remain in contact with culture medium.
This configuration provides a microenvironment that closely resembles physiological conditions of native human skin.

Structural Recapitulation of Human Skin in Skin Organoids

Reconstruction of an integrated epidermal, dermal, and subcutaneous adipose layer

Skin organoids are composed of the epidermis, dermis, and subcutaneous adipose tissue,
mirroring the layered architecture of human skin.
Through controlled dry conditions, the platform further enables the formation of a functional stratum corneum,
achieving a high level of structural and biological similarity to native human skin tissue.

Reproduction of key structural features of human skin

Kangstem Biotech produces mature skin organoids that recapitulate not only the layered skin architecture
but also essential structural features of human skin, including hair follicles, sebaceous glands, and melanocytes.

Application

Skin organoids serve as an integrated human skin evaluation platform,
supporting a wide range of applications across pharmaceutical, cosmetic,
and regenerative medicine research, as well as efficacy and toxicity assessments.

This platform enables diverse experimental and research applications, including drug efficacy evaluation,
drug toxicity testing, hair loss treatment efficacy analysis, regenerative medicine research, skin disease modeling,
and cosmetic efficacy assessment. By providing responses that more closely reflect native human skin biology,
the platform allows for precise evaluation of candidate compounds’ efficacy and safety,
thereby enhancing the reliability of research and product validation.

Skinoid™ is a next-generation skin organoid platform that three-dimensionally recapitulates the structure and functions of human skin.
Skinoid™, based on human-derived cells, recapitulates the interactions among the epidermis, dermis, and skin appendages, thereby providing responses that are more representative of native human skin than those observed in conventional culture models.
Skinoid™ has been designed to be applicable across a wide range of research and industrial fields, including drug efficacy and toxicity evaluation, skin disease modeling, hair loss therapeutic research, regenerative medicine, and cosmetic efficacy testing.

The Skinoid platform utilizes human iPSC–derived skin organoids suitable for alternative testing methods, providing data that closely resemble human skin.

Skinoid platform_UV damaged model

The Skinoid platform is a three-dimensional in vitro model that includes UV damage and atopic disease models,
and can be utilized for new drug development and cosmetic efficacy evaluation.

Skinoid platform_Atopic disease model

Induce Atopic Dermatitis

Inflammatory Cytokine

The Skinoid platform is a three-dimensional in vitro model that includes UV damage and atopic disease models,
and can be utilized for new drug development and cosmetic efficacy evaluation.

Skinoid platform_Permeability evaluation model

Evaluation of Skin Permeability of Cosmetic Devices

Skinoid platform_Hair follicle evaluation model

Evaluation of Hair Growth

The Skinoid platform is being utilized in a variety of studies, including the evaluation of enhanced penetration
using beauty devices and the assessment of drug-induced hair follicle growth.

Kangstem Biotech is developing next-generation hair follicle organoids that reflect the physiological characteristics of human scalp hair follicles. Using pure hair follicles, the company is developing hair follicle grafts for the treatment of hair loss. This technology is advancing as an innovative hair loss treatment solution that goes beyond the limitations of existing therapies.